It uses single-use bioreactors, disposable plastic containers and continuous purification processing
US-based biopharmaceutical company Amgen has completed construction of its first biomanufacturing facility in Singapore.
The new facility, located in Tuas, includes multiple technologies to enable greater speed, productivity and flexibility in commercial-scale manufacturing of biologic medicines.
Built in less than two years, Amgen says the next-generation biomanufacturing facility was completed in half the time required for conventional biomanufacturing plants. It uses single-use bioreactors, disposable plastic containers, continuous purification processing and real-time quality analysis.
The facility is expected to have the same annual output as a conventional facility, and consists of a single building that is said to use less energy and water and have lower solid waste and emission levels.
Amgen also announced plans to break ground on another biomanufacturing facility at Tuas where it will make carfilzomib, the active ingredient for Kyprolis, which is used to treat patients with multiple myeloma.